Latest Biotech News

Parabilis Medicines surged to a blockbuster Nasdaq debut, raising about $670 million as the company drives its tumor-focused pipeline forward. The listing follows another record set by obesity...

SonoThera raised an oversubscribed $125 million in a Series B to advance ultrasound-mediated genetic medicines into clinical development. The financing was led by Vida Ventures and includes...

Life Biosciences has dosed the first participant in a gene therapy trial testing partial cellular reprogramming for glaucoma. The approach turns on three genes intended to “partially reprogram”...

Takeda reported that its oral TYK2 inhibitor zasocitinib (TAK-279) showed statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a Phase 3 top-line readout for moderate...

Oricell Therapeutics said its GPC3-targeted autologous CAR T, Ori-C101, is entering a confirmatory registration Phase 2 trial for patients with GPC3-positive advanced hepatocellular carcinoma. The...

Researchers reported a systemic, non-viral strategy for delivering full-length DMD mRNA using skeletal-muscle-targeted extracellular vesicles (EVs) engineered with targeting tags. In a murine DMD...

Researchers unveiled ErbB-OSV, an engineered vesicular stomatitis virus (VSV) variant designed to selectively kill metastatic ovarian cancer cells while sparing normal tissue. The study reports a...

Biocentury reported that GDF15 is emerging as the lead target in cancer-associated cachexia development, with Pfizer and CatalYm both advancing programs through Phase II/III studies. GDF15 is a...

WuXi AppTec moved to challenge its inclusion on a U.S. military-linked list, filing a lawsuit that disputes the government’s characterization and argues the designation has already caused “severe...

The FDA has approved an adjuvant combination of pembrolizumab and belzutifan for adults with high-risk clear cell renal cell carcinoma following surgery, according to a Dana-Farber-backed report....

GSK has acquired Nuvalent in a $10.6 billion buyout, positioning the company to deepen its oncology pipeline with a targeted strategy. The report frames the transaction around questions that...

Parabilis Medicines’ Nasdaq IPO landed at $670 million, extending a record-breaking run of biotech public listings and signaling that investor appetite is returning to the sector’s highest-profile...

SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated delivery of genetic medicines into clinical development. The round was led by Vida Ventures with...

Life Biosciences in Boston has treated the first participant in a gene therapy trial designed to partially reprogram aged cells, a “reverse aging” approach aimed at restoring youthful cellular...

Researchers have unveiled ErbB-OSV, an engineered vesicular stomatitis virus (VSV) variant designed to selectively target and destroy metastatic ovarian cancer cells while sparing normal tissue....

Amgen is seeking an independent review to defend Tavneos (avacopan) as the FDA weighs potential withdrawal of the rare disease drug. The dispute is tied to FDA concerns about safety and alleged...

Takeda’s zasocitinib (TAK-279) has shown statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a phase III Latitude Atlas readout for moderate-to-severe plaque...

China’s National Medical Products Administration (NMPA) approved Suzhou Alphamab’s HER2 bispecific antibody anbenitamab (KN-026) through priority review for adults with locally advanced or...

Parabilis Medicines closed its IPO at $770.5 million, extending the record pace for biotech capital raising and solidifying its position as a publicly traded conformationally stabilized peptide...

FDA approval has been granted for an adjuvant pembrolizumab–belzutifan combination in high-risk, post-surgery clear cell kidney cancer, according to a Dana-Farber-backed report. The regimen pairs...